The Open-Angle Glaucoma Drugs Market is driven by rising popularity of generic drugs
Glaucoma is a group of eye diseases that damage the optic nerve and causes vision loss if left untreated. Some of the key advantages of glaucoma drugs include providing relief from intraocular pressure, reducing the chance of further vision loss, and stopping the progression of the disease. With rising geriatric population worldwide and increasing prevalence of glaucoma globally, the need for effective treatment options for glaucoma management has increased tremendously.
The open-angle glaucoma drugs market is estimated to be valued at USD 8.51 Bn in 2024 and is expected to reach USD 14.6 Bn by 2031, growing at a compound annual growth rate (CAGR) of 8% from 2024 to 2031.
Key players operating in the open-angle glaucoma drugs market are Novartis, Allergan, Pfizer, Merck, and Santen.
Key players like Novartis, Allergan and Pfizer collectively dominate over 50% of the overall market share due to their widely accepted Open-Angle Glaucoma Drugs Market portfolio and strong global presence. Growing awareness about glaucoma treatment and rising focus on early diagnosis has propelled the demand for glaucoma drugs globally in the recent years. Furthermore, increasing healthcare expenditure and economic stability in developing regions is fueling the expansion of open-angle glaucoma drugs market.
Get more insights on - Open-Angle Glaucoma Drugs Market
Get this Report in Japanese Language: 開放隅角緑内障治療薬市場
Get this Report in Korean Language: 개방각 녹내장 약물 시장
English
Arabic
Français
Español
Português
Türkçe
Dutch
Italiano
Russian
Romaian